Backgrounds: Medulloblastoma (MB) is the commonest brain malignancy in childhood with poor prognosis, because of its rapid aggressive growth and frequent occurrence. The current chemotherapeutic regimens for medulloblastoma patients involve a combination of lomustine,
demonstrated that Res could significantly inhibit the proliferation and induced differentiation and apoptosis of MB cells [11] . For this reason, we tried to gain insights into the mechanism(s) underlying the anti-medulloblastoma effects of resveratrol. SIRT1, the most studied member of Sirtuins family, has been demonstrated to play roles in various biological processes, such as cell growth, differentiation and apoptosis. There is considerable debate on the roles of SIRT1 in tumorigenesis. In some cancers, SIRT1 is a tumor promoter [12] [13] [14] , on the contrary, in other cancers, it acts as a tumor suppressor [15] [16] [17] . So far, it is widely accepted that SIRT1 functions in a cell-tissue context specific manner. It has been reported that SIRT1 involves in the differentiation of neural progenitors [18] [19] and involves in the formation of neural tumor [20] . Limited studies in MB showed that inhibition of SIRT1 expression can induce the apoptosis of DAOY and MED283 MB cells [21] . However, in vivo data about roles of SIRT1 in MBs is absent. Our current study aimed to address this issue.
MATERIALS AND METHODS: Tissue collection and tissue microarray-based immunohistochemical staining
With the consent of patients, MB tissues blocks were collected and prepared in tissue microarrays as described previously [22] . Immunohistochemical staining/IHC was performed on the sections from microarray. Briefly, deparaffinizing and rehydrating the sections, then, retrieving the antigen. After blocked with normal serum, the sections were incubated with solution containing primary polyclonal SIRT1 antibody (1:200, Santa Cruz Biotechnology, Inc, USA). Then the sections were incubated with a horseradish peroxidase conjugated secondary antibody, followed by development with diaminobenzidine and counter-staining with hematoxylin. Experienced pathology technicians reviewed and scored 10 separate fields for each slide. IHC staining was graded on a scale (Table. 1) [23] . Cell culture and treatment: Human UW228-3 MB cells were incubated in DMEM medium supplemented with 10% fetal bovine serum and cultured in a incubator with 5% CO 2 at 37C. The cells were sub-cultured and treated with siRNA sequences against SIRT1 (SIRT1 siRNA) and 100uMRes, respectively. Three independent SIRT1 siRNA and controls were designed and synthesized by Shanghai GenePharma Co., Ltd, China. Res were purchased from Sigma-Aldrich.Co and resolved with DMSO and DMEM medium, respectively, to a stock concentration at 100mM.
Evaluation of SIRT1 expression:
In order to examine the influences of SIRT1 siRNA and Res on MB cells, RT-PCR, ICC and WB were conducted to measure the expression of SIRT1 at transcriptional and translational levels. In RT-PCR, the primer sequences for Sirt1 are: 5'-TCAGTGTCATGGTTCCTTTGC-3' (upward) and 5'-AATCTGCTCCTTTG CCACTCT-3' (downward) (620bp). The reaction were performed according the condition in relate article [24] . The primer sequences for control β-actin are 5'-GCATGGAGTCCTGTGGCAT-3' (upward) and 5'-CTAGAAGCATTTGCGG TGG-3' (downward) (326bp) [25] . In ICC, the polycolonal anti human SIRT1 antiboby was diluted at 1:200 and then added on the coverslips beared with MB cells. WB analyses were performed according previous article [25] . Briefly, prepare lysate from cell culture and determine the protein concentration. Load equal amounts of protein into the wells of the SDS-PAGE gel, along with the molecular weight markers. Then transfer the protein from the gel to the nitrocellulose membrane. After blocking in the 5% blocking buffer in TBS, the membranes were staining with appropriate dilutions of primary antibody SIRT1 (1:800) and p53(acetyl K382) (1:500). Finally, incubate the membrane with solution containing secondary antibody and acquire image using techniques for chemiluminesence.
Flow cytometry (FCM) analysis:
To determine the effects of SIRT1 silencing on cell proliferation, UW228-3 cells treated with or without SIRT1 siRNA were analyzed by FCM. The cells were detached with 0.25% trypsin, washed three times with phosphate buffered saline (PBS; pH7.4) and then fixed with 75% ethanol. The cell samples were re-suspended in 0.5ml PBS and stained with propidium iodide (PI) in the darkness for 30 minutes. The DNA contents were measured by fluorescence-activated cell sorting/FACS on a Becton-Dickinson FACScan flow cytometry system and the data were analyzed using a Cellfit software (Becton, Dickinson and Company).
Statistic analysis
The discrepancy of SIRT1 expression in MB tissue and non-cancerous lesions were evaluated by non-parametric Kruskal-Wallis test (SPSS 11.5).
RESULTS: Up-regulated SIRT1 expression in MB tissues
The expression of SIRT1 protein were detected by IHC staining in 4 tissue microarrays containing 120 MBs and 7 tumor-surrounding noncancerous tissues. As shown in Table 2 , the overall frequency of SIRT1 expression in cancerous tissues is 64.17% (77/120), which is higher than that (14.29%; 1/7) in noncancerous cerebellar tissues (P=0.009). Differential SIRT1 expression in three medulloblastoma subtypes MB tissues were classified into three morphological groups: large cell/anaplastic MB (n=43), classic MB (n=68) and nodular/demoplastic MB (n=9). Analysis of IHC data revealed that the positive rates of SIRT1 protein were different in the three subtypes (Table 2 ). Statistical analysis revealed that the frequencies of SIRT1 expression in the anaplastic/large cell (79.07%) and the classic MB (60.29%) have no statistical difference (P>0.05), but they are higher than that of the nodular/demoplastic (22.22%) subtypes (P<0.05). According to clinical reports [26] [27] , the patients with the nodular MB usually have better prognosis than the other two subtypes.
SIRT1-specific RNAi caused growth inhibition and apoptosis
To explore the role of SIRT1 in survival of MB cells and validate the conclusion of IHC, the viability was detected in MB cells treated with SIRT1 siRNA and mock siRNA. As first, the expression of SIRT1 was manipulated by introducing three SIRT1-siRNA candidates into UW228-3 cells, respectively (Table 3) . The inhibitory influences were evaluated by RT-PCR and WB. The results revealed that the SIRT1 siRNA sequence-1 exhibited better inhibitory effects (about 80%) on SIRT1 transcription and translation, in contrast, no SIRT1 down-regulation was observed in cells transfected with mock siRNA [ Figure 1A ]. The effects of SIRT1 siRNA on proliferation and apoptosis were estimated in the cells treated with or without SIRT1 siRNA sequence-1 for 48 hours. H&E staining and FCM assay revealed that the growth of the cells was suppressed and the apoptosis fractions and proportion of cell at G1 phage increased ( Figure 1B) . A. RT-PCR and Western-blot evaluation of the effects of SIRT1 siRNA on SIRT1 expression at transcriptional and translational levels, which were both downregulated. B. H&E staining showed the decrease of cell number after silencing SIRT1, which was further comfirmed by the FCM analysis. SIRT1 siRNA induced the G1 arrest and appearance of the peak of apoptosis. Figure 2A , 2B]. As a deacetylase, SIRT1 can mediate lots of biological processes by deacetylating target proteins. SIRT1 can suppress the pro-apoptotic activity of p53 by removing the acetylated lysine residue and promote the survival of cancer cells [28] [29] . Since Res is often referred as the activator of SIRT1 [30] , the acetylating level of p53 at 382 lysine has been examined, which shows that the level of p53 (k 382) did not changed significantly after treated with 100uM Res for 48hrs. A. The expression of SIRT1 at transcriptional and translation level were both decreased after treated with Res.
Res suppressed expression but not activity of SIRT1 in MB cells
But Res did not decrease the enzymatic activity of deacetylase SIRT1 as expected by measuring the acetylated p53, the main substrate of SIRT1. B. Similarly, ICC staining ascertained the diminished of SIRT1 protein.
DISCUSSION:
Sirtuins are found in all organisms and act as the critical regulators at the crossroads between cancer and aging [31, 32] . SIRT1, a well understood member of Sirtuin family, modulates several cell signaling pathways in normal and malignant cells [33, 34] . It prevents cell aging and apoptosis of normal cells [35, 36] , while the data obtained from human cancers are controversial because this protein is considered as a tumor promoter in neuroblastomas as well as prostate and skin cancers [37] [38] [39] , but as a tumor suppressor in colon and breast cancers [40, 41] . The conflicting data imply the cell type-related expression and functioning of SIRT1 in human malignancies [42] . It has been proven that SIRT1 is one of the major determinants of neural progenitor cell differentiation [43, 44] . MB is thought to originate from the primitive neuroectodermal cells. We speculated that SIRT1 might play certain role(s) in MB.
Our in vivo data demonstrated that the overall frequency of SIRT1 expression in MB were higher than that in tumor-surrounding tissues. Furthermore, in three major MB subtypes, with different histological features, aggressiveness and the grades of differentiation, SIRT1
proteins expressed differentially. The clinical data revealed that the classic MB and the large cell MB were less differentiated with rapid growth, resulting in unfavorable clinical outcome;
in contrast, the nodular MB were surrounded by extensive fibrogenic tissues with pale nodules of differentiating neuroblasts; consequently, patients with this type usually have relatively better prognosis [26, 27] . Our IHC staining demonstrated that SIRT1 expressed more highly in large cell MB and classic MB than that in nodular MB, indicating the potential link of SIRT1 expression with the biological behavior and poor prognosis of MB. To confirm this notion, it is necessary to suppress SIRT1 expression by RNAi. Our data showed the growth of UW228-3 cells transfected with SIRT1 siRNA was significantly suppressed, accompanied with remarkable G1 phase arrest and apoptosis, consistent with those conducted on human DAOY and D283MED MB cells [21] . UW228-3 cells used in current study are from a classic MB. Since all of them are sensitive to anti-SIRT1 treatments, it would be possible that inhibition of SIRT1 expression may be applicable to different MB subtypes and SIRT1 might be a potential molecular target in the adjuvant management of MB. Our previous data demonstrating anti-tumor activity of Res and present study regarding SIRT1 as a tumor promoter in MB promote us to explore the involvement of SIRT1 in roles of Res. At present, we showed Res can decrease the expression of SIRT1 in UW228-3 MB cells. Moreover, inhibiting the expression of SIRT1 by RNAi suppressed the cell proliferation, caused G1 arrest and trigged apoptotic cell death of MB cells. These above findings propose a possibility that Res play anti-MB roles by inhibiting expression of SIRT1. It is worthy of mentioning that Res is usually referred as the activator of SIRT1 [45] , which deacetylate some tumor suppressor such as p53, FOXOs and Ku70 [46] [47] [48] . SIRT1-mediated deacetylation of p53(K382) decreases p53-mediated apoptosis, and then promotes the survival of cells. Therefore, we propose a question whether the anti-MB activity of Res is associated with its effect on the catalytic activity of SIRT1. In present study, we detected the acetylation of p53, the well-known substrate of SIRT1. ICC and WB data shown the acetylation of p53 at lysine 382 did not change significantly. Regarding other reports question
Res as SIRT1 activator [49] and some function of Res is independent of SIRT1 [50] . We speculated that in MB cells, Res inhibits the proliferation and induces apoptosis in a SIRT1 activity-independent manner, but mainly by suppress the expression of SIRT1.
CONCLUSION:
Collectively, high SIRT1 expression might boost the formation of medulloblastoma.
Resveratrol, a safe polyphenol and easy to intake from common foods, might possess anti-medulloblastoma by regulation the expression but not the enzymatic activity of SIRT1.
Suppressing expression of SIRT1 might be a potential in therapy of medulloblastoma.
